Prothena Corporation plc (PRTA)
PRTANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$8.81
+0.0350 (+0.40%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $8.81 +0.40%
- Market cap
- $452.39m
- P/E
- –
- EPS, last 4 quarters
- $-0.5600
- Dividend yield
- –
- Day range
- –
- 52-week range
- $7.73 to $11.80
- Average volume
- 495.2k
- Previous close
- $8.78
Analysts
4 coveringHold2 buy, 1 hold, 1 sell
Targets a year out average $21.75, +146.9% from here
Earnings
next estimate $0.0200Next report
Dec 2025
+2.2%
Mar 2026
+267.7%
Jun 2026
+17.9%
Sep 2026
+15.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $21.0k | $51.08m | $1.01m | $620.0k |
| Gross profit | $21.0k | $51.08m | $1.01m | $620.0k |
| Operating income | -$24.20m | $30.04m | -$21.10m | -$18.82m |
| Net income | -$21.59m | $32.72m | -$18.58m | -$16.51m |
Last four quarters: revenue $52.73m, margin -45.4%, free cash flow –
News
8 latest- Prothena Consensus Price Target Raised 20.56% to $21.83Fintel · 11 hours ago
- Prothena Corporation plc Reports Third Quarter 2026 Financial ResultsFintel · 4 days ago
- Prothena (PRTA) Reports Q3 Loss, Misses Revenue EstimatesZacks · 5 days ago
- Bristol Myers Squibb to Terminate PRX019 Global License Agreement with Prothena Corporation plcFintel · Oct 29, 2026
- Prothena's Partnership Strategy: Growth Driver or Limitation?Zacks · Oct 20, 2026
- CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?Zacks · Oct 8, 2026
- 4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayZacks · Sep 21, 2026
- KMDA or PRTA: Which Is the Better Value Stock Right Now?Zacks · Aug 14, 2026
The company
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, and Amyotrophic lateral sclerosis (ALS). Prothena is developing and applying CYTOPE, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- prothena.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.